The monoclonal antibodies MOv2 and MOv8, raised against ovarian carcinoma, were found to be directed against two non-crossreacting epitopes expressed on the same molecule. Immunochemical analysis of the MOv8 recognized epitope showed that the Lea oligosaccharide, or commercial anti-Lea MAb, but not the anti-Leb MAb, prevented MOv8 binding to the reference target cell line (SW626), indicating that it is carried by the Lea antigen. Since we previously reported that MOv2 also recognises the Lea antigen, these data suggest that MOv8 and MOv2 were directed against different epitopes on the same oligosaccharide chain. Bearing in mind the knowledge of the biochemical nature of the monoclonal antibody recognized epitopes (CaMOv2 and CaMOv8), the presence of the circulating molecules recognized by them was analyzed by double determinant immunoradiometric assay (DDIRMA) in 103 sera from ovarian carcinoma patients. Patients with clinical evidence of the disease (ED) with MOv2 and MOv8 reactive and negative tumors has sera reactivity in 67% and 19% respectively. Also, 26% of the patients with no clinical evidence of disease (NED) has positive sera. When we investigated the relationship between MOv2-MOv8 DDIRMA sera positivity and red blood cell (RBC) Lewis phenotype, a strong correlation was found between the Lea+ phenotype and DDIRMA sera reactivity in healthy donors (6/6) and in ovarian carcinoma patients (9/10) whatever their clinical condition. No Lea- healthy donors gave evidence of MOv2-MOv8 reactive sera. In contrast, 33% and 57% of the sera from ED carcinoma patients with respectively Lea-b+ and Lea-b- phenotype were positive. In conclusion, the percentage of DDIRMA positive cases previously reported in healthy donors and found here in ovarian carcinoma patients with MOv2 and MOv8 negative tumors or NED, was in agreement with Lea+ phenotype frequency in the normal Caucasian population. However the Lewisa could represent a tumor-associated antigen in ED patients with Lea- phenotyoe and MOv2-MOv8 DDIRMA might be useful for monitoring the disease (Int J Biol Markers 1989; 4: 197-202).
|Number of pages||6|
|Journal||International Journal of Biological Markers|
|Publication status||Published - 1989|
ASJC Scopus subject areas